Cargando…
Multikinase inhibitor-based immunotherapy doublet for advanced hepatocellular carcinoma: its efficacy still needs to be determined
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
AME Publishing Company
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10282687/ https://www.ncbi.nlm.nih.gov/pubmed/37351137 http://dx.doi.org/10.21037/hbsn-23-58 |
| _version_ | 1785061181805821952 |
|---|---|
| author | Li, Heming Hao, Xiangjun Han, Tao |
| author_facet | Li, Heming Hao, Xiangjun Han, Tao |
| author_sort | Li, Heming |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10282687 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | AME Publishing Company |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-102826872023-06-22 Multikinase inhibitor-based immunotherapy doublet for advanced hepatocellular carcinoma: its efficacy still needs to be determined Li, Heming Hao, Xiangjun Han, Tao Hepatobiliary Surg Nutr Letter to the Editor AME Publishing Company 2023-05-18 2023-06-01 /pmc/articles/PMC10282687/ /pubmed/37351137 http://dx.doi.org/10.21037/hbsn-23-58 Text en 2023 Hepatobiliary Surgery and Nutrition. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
| spellingShingle | Letter to the Editor Li, Heming Hao, Xiangjun Han, Tao Multikinase inhibitor-based immunotherapy doublet for advanced hepatocellular carcinoma: its efficacy still needs to be determined |
| title | Multikinase inhibitor-based immunotherapy doublet for advanced hepatocellular carcinoma: its efficacy still needs to be determined |
| title_full | Multikinase inhibitor-based immunotherapy doublet for advanced hepatocellular carcinoma: its efficacy still needs to be determined |
| title_fullStr | Multikinase inhibitor-based immunotherapy doublet for advanced hepatocellular carcinoma: its efficacy still needs to be determined |
| title_full_unstemmed | Multikinase inhibitor-based immunotherapy doublet for advanced hepatocellular carcinoma: its efficacy still needs to be determined |
| title_short | Multikinase inhibitor-based immunotherapy doublet for advanced hepatocellular carcinoma: its efficacy still needs to be determined |
| title_sort | multikinase inhibitor-based immunotherapy doublet for advanced hepatocellular carcinoma: its efficacy still needs to be determined |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10282687/ https://www.ncbi.nlm.nih.gov/pubmed/37351137 http://dx.doi.org/10.21037/hbsn-23-58 |
| work_keys_str_mv | AT liheming multikinaseinhibitorbasedimmunotherapydoubletforadvancedhepatocellularcarcinomaitsefficacystillneedstobedetermined AT haoxiangjun multikinaseinhibitorbasedimmunotherapydoubletforadvancedhepatocellularcarcinomaitsefficacystillneedstobedetermined AT hantao multikinaseinhibitorbasedimmunotherapydoubletforadvancedhepatocellularcarcinomaitsefficacystillneedstobedetermined |